MM-102 TFA is primarily used in research settings to study the role of histone methyltransferases (HMTases) in epigenetic regulation. It is a potent inhibitor of the MLL1 protein, which is involved in the methylation of histone H3 at lysine 4 (H3K4). By inhibiting MLL1, this compound helps researchers investigate the impact of H3K4 methylation on gene expression, cellular differentiation, and disease processes such as cancer. It is particularly valuable in understanding the mechanisms of leukemogenesis, as MLL1 rearrangements are commonly associated with certain types of leukemia. Additionally, MM-102 TFA is utilized in drug discovery efforts to identify potential therapeutic targets for diseases linked to aberrant histone methylation.